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Dynamic genomic changes rescue severe  
SAMD9-related growth restriction in humans 
 
 
 
Patient 
Age at  
delivery 
Age at sample  
(chronological) 
Testosterone  
(ng/dl) 
AMH  
(ng/ml) 
Cortisol 
(µg/dl) 
ACTH 
(pg/ml) 
Interpretation 
3 
34 
weeks 
2 weeks <10 - <0.4 - 
Adrenal and 
Leydig cell 
insufficiency 
4 
31 
weeks 
19 days 106 - <1.8 >1250 Adrenal and 
Leydig cell 
insufficiency 
 
34 days 106 A - - - 
5 
31 
weeks 
8 days <20 - 
5.0  
(2.7 to 2.9) C 
>5000 Adrenal and 
Leydig cell 
insufficiency 
 
5 weeks 250 (post hCG) B - - - 
2 months 92 - - - 
6 
32 
weeks 
3 days 2.9 A - 0.2 - 
Adrenal and 
Leydig cell 
insufficiency, 
normal Sertoli 
cell function 
10 days 5.8 A 23 0.2 >1000 
3 weeks 14 A - - - 
2 months 40 A - - - 
3 months 35 A - - - 
7 
37 
weeks 
6 days 115 - 9.1 82 Partial adrenal 
and Leydig 
cell 
insufficiency 
18 days - - 5.1 114 
7 weeks 389 - - - 
Supplemental Table 1.  Endocrine data (testis, adrenal) 
A Tandem Mass Spectrometry assay instead of immunoassay; B post twice weekly stimulation with 
human chorionic gonadotropin (hCG) for 3 weeks; C basal and peak cortisol in cosyntropin stimulation 
test.  
 
Conversions: testosterone ng/dl to nmol/l, multiply by 0.0347; AMH ng/ml to pmol/l, multiply by 7.14; 
cortisol µg/dl to nmol/l, multiply by 27.6; ACTH pg/ml to pmol/l, multiply by 0.22. 
 
Normal ranges can be dynamic and influenced by preterm delivery. Basal testosterone typically falls in 
the first 5 days after delivery and then rises between 50-90 days in the “minipuberty of infancy” to peak 
around 300-450 ng/l. The timing of the testosterone rise in preterm infants may be delayed compared 
to term babies. AMH concentration in first 2 weeks of life is typically 30 ng/ml. Cortisol basal values 
are typically 5-14 µg/dl and peak response to cosyntropin >20 µg/dl. ACTH normal range 10-60 pg/ml.  
 
Note: immunoassays can be unreliable in preterm infants because of cross reactivity with fetal adrenal 
steroids, although in these children the fetal adrenal output was generally low.  
Patient 
Age at 
delivery 
Age at death  
(chronological) 
Adrenal findings at autopsy Testis findings at autopsy 
1 28 weeks Intrauterine No adrenals found Testes with tubules 
2 28 weeks 1 month No adrenals found 
Tubular structures consistent with 
testes, few Leydig cells 
3 34 weeks 3 months No adrenals found Hypoplastic testes with fibrosis 
4 31 weeks 5 months 
Occasional islands of adrenal 
tissue 
Normal testicular tissue with fewer 
Leydig cells 
Supplemental Table 2.  Autopsy findings 
Fibroblasts                                           ES Patient derived iPSC                ES iMesoderm                                   ES
d
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 Urogenital development   2.58 Urogenital development 6.08 Steroid biosynthesis 3.7 
EGF pathway 2.41 Transcription  3.88 Transcription 3.38 
Sequence specific binding 2.14 Sequence specific binding 3.68 Lung development 3.32 
u
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d
 Cell cycle 15.21 EGF/IGF 7.94 Inflammation 7.41 
Embryonic development 3.92 Embryonic development 5.77 EGF/IGF pathway 6.3 
IGF pathway 1.9 Sequence specific binding 4.62 Apoptosis 3.69 
Supplemental Table 3. Functional enrichment analysis using DAVID 
ES, enrichment score; iPSC, induced pluripotent stem cell; EGF, epidermal growth factor; IGF, insulin-
like growth factor.  
 
Patient Mutation/variant Flanking primers Detection primer 
1 c.1376G>A 
F AAATAAATGCCACCCAGATC 
R TCCACAGAGGACAGTAATAG 
CATCAATGGAGTGGTCAAAGCTTACAAAGAAAGCC 
2 c.2054G>A 
F AGCCTTGAAGAGATCAATGG 
R AAACTGGTTACCTGTTCTCC 
AAAAATCAAGGCATCAAAAGAGGAAGACTTCTATC 
3 and 4 c.2944C>T 
F ATGTGGTCCGGAATATCCTG 
R ATGTTCATCGCGGTGTCTTG 
CAGAGGTCATCGAATGTGGGAACTACTGTGGAGTA 
3 c.4597C>T 
F AAGGAAAAATTGACCAGTGC 
R TGGGTACTGAGATCAAATTC 
AAAAAGTCCAAGAACTTTTGCTTCGTTTACAAGGT 
5 c.2945G>A 
F ATGTGGTCCGGAATATCCTG 
R ATGTTCATCGCGGTGTCTTG 
AGAGGTCATCGAATGTGGGAACTACTGTGGAGTAC 
6 c.2948 T>C 
F ATGTGGTCCGGAATATCCTG 
R ATGTTCATCGCGGTGTCTTG 
GGTCATCGAATGTGGGAACTACTGTGGAGTACGCA 
6 c.2294_2294delA 
F AGCCTTGAAGAGATCAATGG 
R AAACTGGTTACCTGTTCTCC 
ACTAAGGAAGAAATTCAGATGTGCTGTGCTGAAAA 
7 c.3878G>A 
F AAGTAGTGATATTCCAGGGG 
R TGACTGGATTTTGACAGTGC 
GAACAATATTAAGCAAAATGAAGAGGCCAAAACTC 
8 c.4707G>T 
F AAGGAAAAATTGACCAGTGC 
R TGGGTACTGAGATCAAATTC 
TTAGGTCAACTTAGAAGTGGCAGAAGCATAGAGAA 
8 c.1030C>T 
F ATCAAGTCCAACAAGCAAAG 
R GTTACAAGAATGTACTGTTC 
TATGGGAACAAAGTAAAAAATTCTCACTATTTGTG 
Supplemental Table 5. Primer sequences for single nucleotide primer extension assays 
Supplemental Table 4. qRT-PCR primer sequences 
Gene Primer sequence 
SAMD9 
F CAGGACCAGGCAATCTCATT 
R ATCTCCACTCTGCCACAAGG 
GAPDH 
F AGAAGGCTGGGCTCATTTG 
R AGGGCCATCCACAGTCTTC 
ACTB 
F CTGGGACGACATGGAGAAAA 
R AAGGAAGGCTGGAAGAGTGC 
Supplemental Figure 1. SAMD9 is expressed in human fetal testis and adrenal gland. 
(A) Immunohistochemistry showing SAMD9 expression in human fetal testis at 9 weeks post 
conception (red) with NR5A1 (also known as steroidogenic factor-1) shown in green and 
DAPI-stained nuclei in blue. Control data without the primary antibody are shown below. The 
thin layer of DAPI-stained cells is the capsule (C). NR5A1 highlights the nuclei of interstitial 
Leydig cells (L). SAMD9 appears in the cytoplasm of both interstitial cells and cells in the 
seminiferous cords (SC). Scale bar, 100μm. (B) Control data for the fetal adrenal 
immunohistochemistry (Figure 2A). There is some autofluorescence of the cytoplasm of 
adrenal cells in the green channel, but the pattern is distinct from the nuclear staining of 
NR5A1. Scale bar, 100μm.  
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ladder Control 1 Control 2 Control 3 Freiburg Berlin Liverpool NK 
SAMD9 
α-Tubulin 
Western Blot analysis (4 independent experiments) of SAMD9 and α-Tubulin in 
fibroblasts (3 healthy controls and Berlin, Freiburg and Liverpool patient).  
Ladder     Con1     Con2      Con3      Pt 6        Pt 8       Pt 4  
Supplemental Figure 2. SAMD9 protein expression was analyzed by Western blot analysis 
in fibroblast samples from Patients 4, 6 & 8 and compared to the expression of α-tubulin as a 
control. The results were compared with three control fibroblast samples from healthy 
individuals. (A) Example of a representative Western blot. (B) Protein expression analysis 
was performed based on the data of four independent experiments. Data are shown as 
mean ± SEM (* P<0.05, unpaired t-test).  
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Supplemental Figure 3. SAMD9 allele distribution in serial samples from Patients 4 & 6. 
Electropherograms of single nucleotide primer extension reactions in genomic DNA are 
shown from the samples described. PCR products were generated to flank the c.1376G>A 
or c.2054G>A mutation and single nucleotide extension from a specific 35mer primer was 
used to probe the nucleotides at these positions. Fragments were separated on the ABI-
3730 sequencer. The position of a 35b marker is indicated. 
Patient 4 Patient 6 
Leukocytes 
age 1 month 
Fibroblasts 
Bone marrow 
age 5 months 
Leukocytes 
age 15 months 
Leukocytes 
age 4 months 
Leukocytes 
age 1 month 
Bone marrow 
age 20 months 
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Supplemental Figure 4.  Changes in the wild type and mutant allele percentage in different 
tissues and over time to show a selective reduction of the mutant SAMD9 allele with the 
development of monosomy. (A) Serial data from the three children with acquired monosomy. 
The allele percentages were determined using single-nucleotide primer extension assays. 
(B) Blood leukocytes from the two patients who had early monosomy 7 and myelodysplasia. 
Allele percentages were determined by PCR amplification and subcloning of DNA followed 
by sequencing of more than 50 independent clones.   
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Patient 3 
p.Lys27* 
c.79A>T 
Patient 5 
p.Arg1533* 
c.4597C>T 
STOP STOP 
C    A   T    T   A    G     A    T    T 
C    A    T   A   A    G     A    T    T G    G   T    C   G    A    G    C    T  
G    G    T    T  G    A    G    C    T  
Supplemental Figure 5. Low-level nonsense mutations detected in Patients 3 and 5 on 
deep sequencing were confirmed by subcloning. Mutant clones are shown above (mutant 
nucleotide underlined) and wild-type clones are shown below. 
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Supplemental Figure 6. Confirmation of additional loss-of-function nonsense and 
frameshift changes following subcloning of PCR-amplified DNA from Patients 3, 5, 7 and 8. 
Parental DNA was also subcloned for these regions (Patients 3, 5 and 7) and did not show 
any mutations.    
Supplemental Figure 7. Number of vesicles greater than 1.5 μm diameter per cell. Data 
are presented for 20 individual fibroblasts from each patient or control studied by electron 
microscopy. No statistically significant differences were seen between groups.  
Supplemental Figure 8. iPS cells generated from Patients 6 & 8 were karyotyped and 
sequenced in order to confirm no large chromosomal changes had occurred and that the 
primary SAMD9 mutation was present.  
Patient 6 
p.Arg685Gln 
c.2054G>A 
Patient 8 
p.Ile983Ser 
c.2948T>G 
